GREENVILLE, S.C., Jan. 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN), the revolutionary heart monitoring company, announced today that it has completed -- for fabrication and ultimate distribution -- its one-of-a-kind cardiac vest that utilizes Signalife's patented signal amplification technology to allow for precise ECG monitoring of athletes and patients in harsh ambulatory environments. The cardiac vest, featured on November 30, 2006 in an NBC Today Show's segment ("Modern Medical Miracles"), has been extensively utilized in testing in the Champ Car World Series open cockpit racing. During these tests, the ECG signals have allowed physicians to evaluate data previously unavailable when captured in the very harsh environment of a race car. In present cardiac devices, noise and artifact distort ECG recordings in an ambulatory setting. In addition, uncomfortable sticky electrodes are placed on the patient's torso prior to testing. Skin preparation, which may include shaving hair or skin abrading, is often necessary without the Signalife vest. The Signalife proprietary vest features dry (e.g., quarter-size, metal) electrodes embedded in a cloth fabric which provide better comfort and reduced skin irritation for a large percentage of the clients or patients. Signalife is aware of no other system that can acquire a similar ECG signal in any ambulatory environment with the use the metal electrodes compatible with Signalife's cardiac vest. With these approvals, Signalife will now proceed to submit the vest for accelerated FDA clearance and rapid movement into the marketplace. The completion of the cardiac vest coincides with Signalife's business plans to "time" its Gold's Gym initiative with the Company's other exercise programs. The first Gold's Gym facility is fully built out, complete with -- among other things -- the cardiac center and other tools to assist the clientele and physicians in screening related to inherent cardiovascular health fitness. Budimir Drakulic, the Company's Chief Technology Officer, indicated that he was "very satisfied with the development of the vest and its performance during the Champ Car testing." Dr. Drakulic said: "Given the difficulty surrounding the recording of electrocardiographic data during car races, Signalife's R&D team -- and particularly Marko Kostic, the Company's Champ Car project leader -- deserves praise for the successful development of the cardiac vest and accompanying systems. The performance of the vest can be witnessed on video within Signalife's website, www.signalife.com, or by clicking on http://www.msnbc.msn.com/id/3032633/. About Signalife Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company's goal is to become the premier provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife's revolutionary FDA-approved electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a quality ECG signal from ambulatory cardiac patients. The Fidelity 100 will address a portion of the $400 billion cardiac disease market. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. The company's website is available at: http://www.signalife.com Caution Regarding Forward-Looking Statements Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife, Inc. results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approval governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Signalife's products or services, adverse equity market conditions and declines in the value of Signalife's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.